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Summary
The aim was to assess the usefulness of TGF-β1 and elastase in the evaluation of activity of 
ulcerative colitis (UC) and Crohn’s disease (CD).
32 patients diagnosed with UC, 31 with CD and 30 healthy volunteers were enrolled in this study. 
Diagnosis of the disease was confirmed by videocolonoscopy and histopathological evaluation 
of intestinal biopsies. Disease activity was assessed by use of the Mayo Scoring System for 
Assessment of Ulcerative Colitis Activity in UC patients and by CDAI in CD patients. hsCRP was 
determined by the immunonephelometric method, TGF-β1 and elastase plasma concentration 
by ELISA. The results of the study were analyzed using Statistica and R statistical language.
In UC a positive correlation between disease activity and platelet level, hsCRP and TGF-β1 
concentration was noted. Elastase concentration in UC patients was significantly higher than 
in CD, but there was no correlation with the activity of the disease. In CD patients we observed 
a positive correlation between disease activity and leukocytes, platelet levels and elastase 
concentration, and a very low correlation with hsCRP and TGF-β1.
Determination of TGF-β1 can be used for evaluation of inflammatory activity in UC and it is 
connected with elevated concentrations of CRP and platelets. To a lower extent TGF-β1 can also 
be used for evaluation of inflammatory activity in CD. Examination of elastase concentration 
may be useful in the assessment of CD activity. Plasma elastase concentration may be helpful 
in UC and CD differentiation. The preliminary results of this investigation seem promising; 
nevertheless, more studies are necessary. 
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IntroductIon
Inflammatory bowel disease (IBD) comprises two types 
of chronic intestinal inflammation – ulcerative colitis 
(UC) and Crohn’s disease (CD). The etiology is unknown; 
however, dysfunction of the immunological system and 
inappropriate production of mucosal cytokines play the 
major roles [7]. As the prevalence of IBD increases, it is 
important to find a biochemical marker that can be used 
in early detection of disease exacerbation, treatment 
monitoring and in the differential diagnosis.
Inappropriate production of mucosal cytokines and 
impaired balance between pro- and anti-inflammatory 
cytokines play a crucial role in mucosal injury in IBD. 
Proinflammatory cytokines, such as interleukin-1beta 
(IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), and 
tumor necrosis factor-alpha (TNF-α), are produced 
and released by macrophages and monocytes in infla-
med mucosa. Transforming growth factor-beta1 (TGF-
β1), interleukin-10 (IL-10) and interleukin-11 (IL-11) 
are the most important anti-inflammatory cytokines 
[3,10,11]. Transforming growth factor-beta (TGF-β) 
plays a great role as an inducer of fibrosis and myofi-
broblast generation and in a biological process cal-
led epithelial-to-mesenchymal transition (EMT) in 
colonic diseases [12]. EMT is a well-established bio-
logical phenomenon important in normal tissues and 
organ development and in the pathogenesis of dise-
ases (such as chronic inflammation-related fibro-
sis, colorectal carcinogenesis, cancer invasion and in 
mucosal healing) [12]. The inhibition of EMT seems to 
minimize chronic inflammation-related wall fibrosis 
in colon [12]. In IBD, TGF-ß1 produced and secreted 
from the cells in the lamina propria and the epithe-
lium of the colon controls proliferation and takes part 
in healing and fibrosis [8].
Granulocyte elastase (elastase) is a neutral proteinase 
released from granulocytes and plays an important role 
in intestine injury and inflammation. Infiltration of 
bowel mucosa by neutrophils and eosinophilic granulo-
cytes is a characteristic feature of chronic inflammatory 
bowel disease [4]. 
As far as we know, there are no precise data about TGF-
β1 and elastase in patients with IBD. Moreover, some 
conclusions of these studies seem to be contradictory. 
We performed a pilot study aiming to assess the useful-
ness of plasma TGF-β1 and elastase in the evaluation of 
UC and CD activity. The study was approved by the local 
ethical committee at the UJ.
MaterIal and Methods
We assessed plasma concentration of TGF-β1, granulo-
cyte elastase, hsCRP (high sensitivity CRP), and levels of 
platelets (PLT) and white blood cells (WBC) in patients 
suffering from UC or CD and in healthy volunteers. 
Thirty-two patients diagnosed with UC, 31 with CD and a 
group of 30 healthy volunteers matched for age and gender 
were enrolled in this study. Diagnosis of IBD was confirmed 
by videocolonoscopy and histopathological evaluation of 
intestinal biopsies. Patients with IBD were hospitalized in 
the Department of Gastroenterology, Hepatology and Infec-
tious Diseases of the University Hospital in Cracow. 
The activity of UC was assessed according to the Mayo 
Scoring System including stool frequency, rectal ble-
eding, endoscopic findings and physician’s global asses-
sment. In the group of patients with UC, 50% (16) had 
severe disease (activity score 10-12 points), 40.6% (13) 
moderate-severe disease (activity score 6-9 points) and 
9.4% (3) mild disease (activity score 2-5 points).
The activity of CD was measured using the Crohn’s Dise-
ase Activity Index (CDAI), which includes the number of 
liquid or very soft stools in one week, the sum of seven 
daily abdominal pain ratings, general well-being, symp-
toms or findings presumed related to Crohn’s disease, 
taking loperamide or opiates for diarrhea, abnormal 
mass, hematocrit and weight. In the group of patients 
with CD, 59.4% (19) had moderate disease (activity score 
220-450 points), 21.8% (7) severe disease (activity score 
>450 points) and 15.6% (5) mild disease (activity score 
150-220 points).
All laboratory tests from peripheral blood samples were 
performed in the Department of Clinical Biochemistry, 
Jagiellonian University Medical College. Leukocytes, 
platelet levels, hsCRP, TGF-β1 and elastase concentra-
tions were determined in all groups. hsCRP was deter-
mined by the immunonephelometric method (Behring 
Nephelometer 100 Analyser and reagent N High Sensiti-
vity CRP from DADE Behring firm, Marburg, Germany). 
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TGF-β1 was measured by the immunoenzymatic ELISA 
method using specific ELISA kits (DIACLONE, France). 
Elastase was determined by the immunoenzymatic 
ELISA method using specific ELISA kits (Human PMN 
Elastase, BioVendor, Czech Republic).
Statistical analysis was performed using R statistical lan-
guage (a free software environment for statistical com-
puting and graphics) and Statistica. Variance analysis, 
Student’s t-test, Pearson’s r correlation, Wilcox, and 
Spearman’s rho correlation were used.
results
The levels of WBC, PLT and plasma concentrations of 
hsCRP, TGF-β1 and elastase were statistically higher in 
patients with active UC than in the healthy controls 
(p<0.001). 
The levels of WBC and PLT, and plasma concentra-
tions of hsCRP and TGF-β1 were statistically higher in 
patients with active CD than in the healthy controls 
(p<0.001). There was no significant difference in ela-
stase concentration between CD patients and healthy 
controls (p=0.18).
There was no significant difference in the levels of 
WBC, PLT, hsCRP, and TGF-β1 between the UC and CD 
patients. However, there was a significant difference in 
the mean elastase concentration between the patients 
with UC and CD (p=0.011, UC: 61.97±27.46 ng/ml,   
CD: 47.56±14.00 ng/ml). 
Table 1. The description of the subgroups and the comparison of the subgroups in terms of the parameters. 
Parameter 
[reference values]
Patients with UC Patients with CD Control group 
p
UC/C
p
CD/C
p
UC/CD
Number of people N=32 N=31 N=30 - - -
Average age 
[years]
32.7 (min.18, 
max.55)
32.5(min.21, 
max.50)
33.6 (min.23, max 
50)
- - -
Female N=16 (50%) N=13 (42%) N=13 (43%) - - -
Smokers N=11 (34%) N=4 (13%) N=17 (56%) - - -
WBC [4-10x 103/
mm3]
8.9±3.26 7.74±2.71 6.37±1.40 P=0.001 P=0.049 SI
Platelets [125-340 
x 103/mm3]
382.78±73.32 349±109.14 230.50±44.62 P<0.001 P<0.001 SI
hsCRP [<5mg/l] 41.53±33.30 40.84±24.81 2.88±1.29 P<0.001 P<0.001 SI
TGFβ1 
[2.1-6.1 ng/ml]
12.69±6.01 11.25±5.94 5.12±2.77 P<0.001 P<0.001 SI
Elastase [24.7-
90.4ng/ml]
61.97±27.46 47.56±14.00 43.36±10.13 P<0.001 P=0.18 P=0.011
*p<0.05; SI: statistically insignificant. CD: Crohn’s disease. UC: ulcerative colitis. C: group of healthy control. WBC: white blood cells. CRP: high sensitivity C-reactive 
protein. Elastase: granulocyte elastase. TGF β1: transforming growth factor-beta1.
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Figure 1. 
Fig. 1.  Mean levels of granulocyte elastase (elastase) and transforming growth factor-beta1 (TGF, TGF-β1) in patients with UC (ulcerative colitis), CD (Crohn’s 
disease) and healthy controls (Control)69
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significantly higher than in CD patients, there was no 
correlation with the activity of the disease. 
•   in CD a positive correlation between increased con-
centration of elastase (correlation coefficient was 0.6; 
p<0.001), platelets (0.75; p<0.001) and severity of the 
disease was noted. A lower one was found between the 
concentration of TGF-β1 (0.43; p=0.016), hsCRP (0.37; 
p=0.039) and WBC (0.36; p=0.05) and disease activity. 
dIscussIon
The present study carries three messages that we believe 
to be important. Firstly, TGF-β1 might differentiate 
active from inactive UC, which is consistent with a few 
previous studies. Secondly, elastase level may be useful 
in the evaluation of CD activity. Finally, serum elastase 
level may be helpful in UC and CD differentiation. There 
are only a few publications concerning TGF-β1 or elas-
tase in patients with IBD. The majority of studies have 
assessed cytokines in colonic mucosa or stool. However, 
we found no study involving plasma TGF-β1 and elastase 
together in such a group of patients. Some of the results 
are incoherent. 
TGF-β1
Our study has shown that TGFβ1 might be considered 
as a sensitive marker of UC activity. Indeed, Kiliç et al. 
We also analyzed the correlation between the measu-
red parameters in the patients with IBD and the control 
group: 
•   in UC, a low positive correlation between increased 
concentration of TGF-β1 and elevated concentration of 
hsCRP (the correlation coefficient was 0.57; p<0.05) and 
platelets (the correlation coefficient was 0.42; p<0.05) 
was found. 
•   in CD a low positive correlation between increased con-
centration of TGF-β1 and elevated level of platelets was 
observed (the correlation coefficient was 0.46; p<0.05). 
Additionally, a low positive correlation between incre-
ased concentration of elastase and increased level of 
platelets (0.39; p<0.05) and hsCRP (0.36; p<0.05) was 
noted. 
No statistical correlation between increased concentra-
tion of TGF-β1 and elastase was found in all groups.
We also analyzed the correlation between the measu-
red parameters and the activity of the disease in the 
patients with IBD:
•   in UC a low positive correlation between increased 
concentration of TGF-β1 (correlation coefficient was 
0.86; p<0.001), CRP (0.75; p<0.001), number of platelets 
(0.53; p=0.002) and severity of the disease was found. 
Although elastase concentration in UC patients was 
Table 2.  Rho-Spearman correlation coefficients between variables in patients with UC and r-Pearson correlation coefficients between variables in CD and healthy 
controls.
UC WBC PLATELETS hsCRP ELASTASE TGF-β1
WBC - 0.14 0.02 -0.03 0.05
PLATELETS 0.14 - 0.49* 0.15 0.42*
hsCRP 0.02 0.49* - 0.04 0.57*
ELASTASE -0.03 0.15 0.04 - 0.10
TGF-β1 0.05 0.42* 0.57* 0.10 -
CD WBC PLATELETS hsCRP ELASTASE TGF-β1
WBC - 0.55* 0.25 0.17 0.34
PLATELETS 0.55* - 0.33 0.39* 0.46*
hsCRP 0.25 0.33 - 0.36* 0.23
ELASTASE 0.17 0.39* 0.36* - 0.24
TGF-β1 0.34 0.46* 0.23 0.24 -
CONTROL WBC PLATELETS hsCRP ELASTASE TGF-β1
WBC - 0.08 -0.20 0.08 -0.20
PLATELETS 0.08 - 0.01 0.15 0.41*
hsCRP -0.20 0.01 - 0.21 -0.01
ELASTASE 0.08 0.15 0.21 - -0.16
TGF-β1 -0.20 0.41* -0.01 -0.16 -
*p < 0.05. CD: Crohn’s disease. UC: ulcerative colitis. C: group of healthy control. WBC: white blood cells. CRP: high sensitivity C-reactive protein. Elastase: granulocyte 
elastase. TGF β1: transforming growth factor-beta1.70
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Some studies were conducted in pediatric patients and 
the conclusions seem to be surprising. Kader et al. mea-
sured TGF-β1 level in serum of 65 children suffering 
from CD and 23 from UC [6]. They noted that TGF-β1 
was significantly higher in patients with CD in remis-
sion than in active disease [6]. There was no significant 
difference in UC patients. In our study TGF-β1 level in 
serum was higher in both UC and CD patients. Further-
more, it correlated with IBD activity.
In another pediatric study, Wedrychowicz et al. asses-
sed the influence of exclusive enteral nutrition on 
serum concentration of TGF-ß1 and vascular endothe-
lial growth factor (VEGF) in 39 children and adolescents 
with IBD (24 with CD and 15 with UC) [13]. At the base-
line they found increased serum TGF-ß1 in UC patients 
versus the CD group and controls [13]. 
Elastase 
Initial studies demonstrated that elastase level in serum 
may potentially be a marker for IBD. Fishbach et al. inve-
stigated plasma elastase in 44 patients with CD and UC; it 
was significantly higher in these patients in comparison 
to 7 patients with non-inflammatory bowel diseases or 
53 healthy controls [4]. Moreover, elevated plasma levels 
were more often observed in patients with active inflam-
mation than in those with inactive disease. However, it 
did not correlate with WBC level, nor with clinical indi-
ces, and not always with IBD activity [4]. Scientists conc-
luded that elastase did not reliably indicate IBD activity. 
noted that in UC, the mean level of TGF-ß1 in active dis-
ease was higher than in remission and can be used as a 
marker for differential diagnosis of these stages [8]. In 
their study they enrolled 70 patients with IBD (UC or CD) 
and 20 controls [8]. 
In a few studies TGF-β was measured in bowel tissue 
by an immunohistochemical method. Kanazawa et al. 
studied the expression of TGF-β (1,2,3) in paraffin-
embedded samples from bowel tissue and the con-
centration in blood: basic fibroblast growth factor 
(b-FGF), endothelin-1 (ET-1) and vascular endothelial 
growth factor (VEGF) [7]. They examined 11 patients 
with UC, 11 with CD and 10 healthy controls [7]. 
Expression of TGF-β1 in the endothelial cells was not 
found in either the UC or the CD group [7]. They noted 
moderate or weak expression of transforming growth 
factor-beta2 (TGF-β2) and transforming growth fac-
tor-beta3 (TGF-β3) in the inflammatory cells in 5 (of 
7) cases of active UC and in 4 (of 6) cases of active CD 
[7]. In contrast, in our study an increased concentra-
tion of TGF-β1 in blood was found, both in UC and CD 
patients.
In the earlier study also Babyatsky et al. assessed TGF-β 
(and TGF-α) in colonic mucosa from patients with UC, 
CD and healthy controls [2]. TGF-β levels were increased 
in affected mucosa [2]. Scientists concluded that TGF-β 
might be the key cytokine during periods of active 
inflammation [2]. However, there was no distinction 
between the types of TGF-β.
Fig. 2.  Scatter plot with regression lines. CD: Crohn’s disease. UC: ulcerative colitis. Control: the healthy controls. Elastase: granulocyte elastase. TGF-β1: transforming 
growth factor-beta1 (TGF)71
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In our study there was no significant difference in ela-
stase between CD patients and healthy controls. Howe-
ver, elastase appeared to be more useful in determining 
CD severity.
The different results of TGF-β1 and elastase in CD 
and UC in our study may be connected with different 
microscopic extent of inflammation in the two dise-
ases. Inflammation in CD evolves from superficial into 
transmural, resulting in deep fissuring ulcers pene-
trating through the muscle layer, forming fistulas and 
ulcers, whereas in UC, it is limited to mucosa and sub-
mucosa. The pathophysiology of this phenomenon is 
still unknown and may be connected with an imba-
lance between proteases, such as elastase, and their 
inhibitors.
conclusIons
From the present study we concluded that:
•   TGF-β1 as well as CRP, platelets and WBC can be useful 
in the early diagnosis of IBD exacerbation. TGF-β1 can 
be used for evaluation of inflammation activity in UC 
and it is connected with the elevated concentration of 
CRP and platelets. To a lower extent, TGF-β1 can also 
be used for evaluation of inflammatory activity in CD. 
•   Examination of elastase concentration as well as pla-
telets may be useful in the assessment of CD activity. 
•   Plasma elastase concentration may be helpful in UC 
and CD differentiation.
•   The preliminary results of this investigation seem pro-
mising; nevertheless, more studies are necessary to 
establish new diagnostic strategies that can be efficien-
tly used in clinical practice in the near future.
In our study the mean elastase concentration was signi-
ficantly higher in UC, but ultimately correlated with CD 
activity.
To examine whether plasma elastase represents a relia-
ble laboratory marker for establishing the activity of 
IBD, Gouni-Berthold et al. measured plasma elastase 
concentration in 61 patients suffering from CD or UC, 
and compared them with 40 healthy controls [5]. Pla-
sma elastase concentration was significantly higher in 
patients with IBD than in healthy controls, and signi-
ficantly higher in active disease than in remission [5]. 
They concluded that elastase may be a practical mar-
ker of IBD activity, especially for identifying patients in 
remission [5]. In our study, the conclusions seems less 
promising – only in CD patients did elastase level corre-
late with activity of the disease.
Andus et al. also studied plasma elastase concentration, 
comparing it to fecal elastase concentration in CD and UC 
patients [1]. According to the results, the plasma elastase 
level correlated with IBD and its activity; however, the 
fecal elastase level correlated only with UC activity [1].
Also Langhorst et al. examined fecal levels of polymor-
phonuclear neutrophil (PMN)-elastase, lactoferrin, cal-
protectin and serum CRP in 139 patients (54 with IBS, 
42 with UC and 43 with CD) [9]. All patients with IBD 
underwent videocolonoscopy, determining disease acti-
vity with CAI or CDAI respectively [9]. Scientists found 
significantly higher levels of all parameters in CD and 
UC patients with active inflammation compared with 
patients with inactive inflammation or IBS. They conclu-
ded that elastase enables active IBD to be differentiated 
from inactive IBD or IBS, and that it is superior to CRP in 
its diagnostic accuracy [9].
Table 3. Rho-Spearman correlation coefficients between measured parameters and the degree of disease’s activity in patients with UC and CD.
Parameter [reference values]
The degree of UC activity
p Rho-Spearman
WBC 0.833 0.04
PLATELETS 0.002 0.53*
hsCRP < 0.001 0.75*
ELASTASE 0.358 0.17
TGF β1 < 0.001 0.86*
Parameter [reference values]
The degree of CD activity
p Rho-Spearman
WBC 0.050 0.36*
PLATELETS < 0.001 0.75*
hsCRP 0.039 0.37*
ELASTASE < 0.001 0.60*
TGF β1 0.016 0.43*
*p < 0.05. CD: Crohn’s disease. UC: ulcerative colitis. WBC: white blood cells. CRP: high sensitivity C-reactive protein. Elastase: granulocyte elastase. TGF β1: transform-
ing growth factor-beta1.72
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